Rush Medical Center Home Page Information for healthcare Professionals Rush University
FIND A DOCTOR
PATIENT & VISTOR SERVICES
HEALTH INFORMATION
CLINICAL SERVICES
EVENTS & CLASSES
RUSH NEWS ROOM
CLINICAL TRIALS
RESEARCH AT RUSH
NURSING AT RUSH
WORK AT RUSH
GIVING TO RUSH

Bookmark This Page
Clinical Trails at Rush Prostate Cancer Study
Clinical Trial Protocol ID
04020510

Clinical Trial Investigator Name
Dennis Pessis, MD

Clinical Trial Title

Phase 3, double blind trial, using investigational product in asymptomatic subjects with Gleason sum equal to or lesser than 7, metastatic androgen independent prostatic adenocarcinoma



Clinical Trial Protocol Description

An investigational product will be used for the treatment of asymptomatic, metastatic, androgen independent prostate adenocarcinoma. The objective of the trial is to assess the safety and the effectiveness of the investigational product in delaying the progression of prostate cancer and delaying onset of disease-related pain.



Clinical Trial Eligibility Criteria

 You may be eligible for this study if:

  • You have a histologically documented adenocarcinoma of the prostate with Gleason score of 7 or lower
  • You have metastatic disease as evidenced by soft tissue and/or bony metastases on imaging studies
  • You have current or historical evidence of disease progression concomitant with surgical or medical castration
  • You have a serum PSA greater than 5ng/dl
  • You are a man over the age of 18 
  • You have a life expectancy of at least six months

This is a partial list of eligibility criteria.





Contact Name Dennis Pessis, MD
Contact Phone (312) 563-3447
Contact E-mail clinical_trials@rush.edu
Promotional Information

Clinical Trials Home
Cancer Clinical Trials
Prostate Cancer Study

   
Find a Doctor | Patient & Visitor Services | Health Information
Clinical Services | Events & Classes | Rush News Room | Clinical Trials
Research At Rush
Disclaimer | Privacy Statement | Site Map

© Rush University Medical Center, Chicago, Illinois